PuraPharm Corporation Limited (HKG:1498)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
0.330
+0.020 (6.45%)
At close: Mar 10, 2026
-40.00%
Market Cap 176.57M
Revenue (ttm) 346.76M
Net Income (ttm) -38.56M
Shares Out 535.05M
EPS (ttm) -0.10
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 79,000
Average Volume 142,100
Open 0.310
Previous Close 0.310
Day's Range 0.310 - 0.340
52-Week Range 0.300 - 0.650
Beta 0.10
RSI 49.62
Earnings Date Mar 30, 2026

About PuraPharm Corporation

PuraPharm Corporation Limited, an investment holding company, engages in research, development, production, and sale of concentrated Chinese medicine granule (CCMG) and Chinese healthcare products in Hong Kong, Mainland China, and internationally. It operates through five segments: China CCMG, Hong Kong CCMG, Chinese Healthcare Products, Clinics, and Plantation. The company offers over the counter health products under the PuraGold, Oncozac, Haveron, and Immuzac brand names. It also provides Chinese medicine clinic management system for general... [Read more]

Sector Healthcare
Founded 1998
Employees 469
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1498
Full Company Profile

Financial Performance

In 2024, PuraPharm Corporation's revenue was 382.09 million, a decrease of -6.09% compared to the previous year's 406.86 million. Losses were -35.44 million, -66.59% less than in 2023.

Financial Statements

News

There is no news available yet.